Diabetic Neuropathy - Pipeline Insight, 2024

This “Diabetic Neuropathy- Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Neuropathy Understanding

Diabetic Neuropathy: Overview

Diabetic Neuropathy, is nerve damage that can occur in people with diabetes. Different types of nerve damage cause different symptoms. Symptoms can range from pain and numbness in your feet to problems with the functions of your internal organs, such as your heart and bladder. The signs and symptoms of diabetic neuropathy usually take several years to appear. Signs and symptoms will depend on which type of neuropathy and nerves it affects. The symptoms of peripheral neuropathy include: numbness, pain, tingling, and burning sensations starting in the toes and fingers then continuing up the legs or arms, loss of muscle tone in the hands and feet, not being able to feel heat, cold, or physical injury, loss of balance. Proximal neuropathy can lead to pain in the lower body, often on one side, and weakness in the legs. Symptoms of focal neuropathy can vary widely, depending on the nerve affected. Focal neuropathy and cranial neuropathy can both lead to visual disturbances, such as double vision. People with diabetic neuropathy often do not realize they have it until the symptoms are more advanced. If the doctor suspects diabetic neuropathy, some diagnostic tests are done, such as: an electromyogram (EMG), which records electrical activity in the muscles, a nerve conduction velocity test (NCV) which records the speed at which induced signals pass through the nerves. Most types of diabetic neuropathy gets worse over time. The first step for people with any type is to bring blood sugars within a target range agreed with a doctor and manage high blood pressure and cholesterol levels. Managing glucose levels will minimize the risk of diabetic neuropathy. A key part of treatment focuses on reducing pain and managing some of the symptoms. People should also avoid or stop smoking and limit their alcohol intake to a maximum of one drink a day for women and two for men. Physical therapy, used in combination with medications, might help relieve pain and reduce the risk of dependency on opioids.

Diabetic Neuropathy- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathy.

Diabetic Neuropathy Emerging Drugs Chapters

This segment of the Diabetic Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Neuropathy Emerging Drugs

Nidufexor: Novartis Nidufexor (LMB763), a compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabeticnephropathy.

SER 150: Serodus SER150 is an anti-inflammatory compound with a novel mode of action both inhibiting thromboxane synthase as well as blocking the thromboxane (TP) receptor. SER150 is expected to specifically inhibit the inflammatory processes in the renal arterioles and glomeruli and reduce the progression of renal impairment whereby the amount of protein excreted in urine will decrease. Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic nephropathy but that treatment does not inhibit the fundamental causes of renal damage nor does it cure the disease. Since the inflammation is a progressive process causing loss of the renal function, SER150 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic nephropathy. It is expected that SER150 treatment delays progression or even prevents development of the disease. Consequently, SER150 has a blockbuster marketpotential.

GFB 887: Goldfinch Bio GFB-887 is designed to treat patients with kidney diseases associated with over-activation of the TRPC5-Rac1 pathway. The treatment involves an oral medication given one time daily. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diabeticneuropathy.

Diabetic Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Neuropathy

There are approx. 25+ key companies which are developing the therapies for Diabetic Neuropathy. The companies which have their Diabetic Neuropathy drug candidates in the most advanced stage, i.e. Phase II include, Serodus.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathy drugs.

Diabetic Neuropathy Report Insights

• Diabetic Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Neuropathy drugs?
• How many Diabetic Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Goldfinch Bio
• Novartis
• Serodus
• CURACLE
• Daiichi Sankyo
• NeuroBo Pharmaceuticals
• Dong-A Pharmaceutical

Key Products

• Nidufexor
• SER 150
• GFB 887
• CU 01
• SER 130
• Esaxerenone
• NB-01

This product will be delivered within 1-3 business days.